A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
Status:
Completed
Trial end date:
2016-12-07
Target enrollment:
Participant gender:
Summary
MM-398 (also known as PEP02) is nanoliposomal encapsulated irinotecan: the liposomal
formulation is designed to extend plasma circulation and to increase accumulation in the
tumor through the enhanced permeability and retention (EPR) effect.
This study introduces a new concept of combining free and nanoliposomal drugs.
Phase:
Phase 1
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)